These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7086265)

  • 1. Efficacy of a new sustained release procainamide preparation: evaluation with 24-hour Holter monitoring.
    Garcia JR; Godley ML; Freedman RJ
    J La State Med Soc; 1982; 134(1):8-9. PubMed ID: 7086265
    [No Abstract]   [Full Text] [Related]  

  • 2. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
    Henningsen P; Laursen HB; Christiansen BD; Moller J
    Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
    [No Abstract]   [Full Text] [Related]  

  • 4. The assessment of an antiarrhythmic agent, sustained-release procainamide, with the aid of Holter monitoring.
    Bauer GE; Mitchell AS; Bates F; Hellestrand K
    Med J Aust; 1977 Nov; 2(22):733-5. PubMed ID: 347229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical use of sustained-release procainamide in treatment of cardiac arrhythmias.
    Michelson EL; McGeehin FC; Levin BK
    Angiology; 1988 Jul; 39(7 Pt 2):647-54. PubMed ID: 3044199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agranulocytosis due to new sustained-release procainamide.
    Berger BE; Hauser DJ
    Am Heart J; 1983 Jun; 105(6):1035-6. PubMed ID: 6858823
    [No Abstract]   [Full Text] [Related]  

  • 8. A new sustained-release tablet formulation of procainamide.
    Fremstad D; Dahl S; Jacobsen S; Lunde PK; Nådland KJ; Marthinsen AA; Waaler T; Landmark KH
    Eur J Clin Pharmacol; 1973 Dec; 6(4):251-5. PubMed ID: 4591152
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
    Kalin ML; Babich MF; Klinke WP; Hui WK
    Can J Cardiol; 1990; 6(1):15-8. PubMed ID: 2310989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
    Pirovino M; Karlaganis G; Galeazzi RL
    Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procainamide in plasma following administration of sustained-release tablets in acute myocardial infarction.
    Ihlen H; Skomedal T; Stafsnes H; Ditlefsen EM
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):257-62. PubMed ID: 805020
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets.
    Arstila M; Katila M; Sundquist H; Anttila M; Pere E; Tikkanen R
    Acta Med Scand; 1974 Mar; 195(3):217-22. PubMed ID: 4595254
    [No Abstract]   [Full Text] [Related]  

  • 14. [Arrhythmia prophylaxis with procanamide: inadequate dosage?].
    Collste P; Karlsson E; Norlander B; Sievers J; Sjöqvist F
    Lakartidningen; 1972 Jun; 69():Suppl 2:47-50. PubMed ID: 4645697
    [No Abstract]   [Full Text] [Related]  

  • 15. Ambulatory monitoring in the controlled assessment of anti-arrhythmic drug therapy.
    Jewitt D; McComish M; Jackson G
    Postgrad Med J; 1976; 52 Suppl 7():67-72. PubMed ID: 796837
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma levels of procaine amide after administration of conventional and sustained-release tablets.
    Karlsson E
    Eur J Clin Pharmacol; 1973 Dec; 6(4):245-50. PubMed ID: 4591151
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of a sustained release procainamide preparation.
    Flanagan AD
    Angiology; 1982 Feb; 33(2):71-7. PubMed ID: 7039427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical aspects and treatment of paroxysmal forms of cardiac rhythm disorders].
    Vasilenko VKh; Golochevskaĭa VS; Fomina IG
    Ter Arkh; 1973 Dec; 45(12):46-55. PubMed ID: 4779666
    [No Abstract]   [Full Text] [Related]  

  • 19. Maintenance therapy with a new retard tablet preparation of procainamide.
    Hansteen V; Landmark KH; Fremstad D; Dahl SG; Jacobsen S; Marthinsen AA; Waaler T; Frislid K; Lunde PK
    Am Heart J; 1976 Jul; 92(1):47-56. PubMed ID: 785987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH; Rocci ML; Porrini KA; Greenspon AJ; Ferguson RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.